Article Text
Therapeutics
Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation
Statistics from Altmetric.com
Footnotes
-
↵* See glossary.
-
For correspondence: Dr J L Halperin, Mount Sinai Medical Center, New York, NY, USA; jonathan.halperinmsnyuhealth.org
-
Source of funding: Astra-Zeneca.